Showing 3 posts of 3 posts found.

NICE greenlights Roche’s Rozlytrek for ROS1+ advanced non-small cell lung cancer

June 15, 2020
Sales and Marketing NICE, Roche, Rozlytrek, UK, lung cancer

Roche’s Rozlytrek (entrectinib) has secured recommendation for NHS use in England and Wales after NICE backed the drug in final …

Roche’s cancer drug Rozlytrek scores double approval from FDA

August 16, 2019
Medical Communications Cancer, Roche, Rozlytrek, lung cancer, oncology

The FDA has approved Roche’s Rozlytrek (entrectinib) as a treatment for adults with ROS1-positive, metastatic non-small cell lung cancer (NSCLC). …

Roche secures world first with Japanese Rozlytrek approval in advanced recurrent solid tumours

June 18, 2019
Manufacturing and Production, Sales and Marketing Cancer, Japan, Roche, Rozlytrek, pharma

Roche’s personalised cancer therapy Rozlytrek (entrectinib) has seen its first approval: the drug has been approved in Japan for the …

Latest content